Back to Awarded Treatment Trials
Awarded Trial: 02T-244
Grant ID
02T-244
Illness
Schizophrenia (first episode)
Primary Drug/Intervention
Minocycline
Primary Dosage
200 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Mendlovic
Sample Size
210
Duration of Study Period for Each Subject
24 weeks
Outcome Measurements
Cognitive battery, CGI, PANSS, SANS
Results
Minocycline is a second-generation tetracycline with anti-inflammatory and neuroprotective effects. It also counteracts the behavioral effects of NMDA receptor antagonists. Patients enrolled in the trial underwent a 2-week placebo lead-in and were then randomized to receive minocycline (n=36) or placebo (n=18) for 22 weeks. Fifty percent of patients receiving minocycline lost weight while 100% on placebo gained weight. Minocycline was associated with significant improvement in negative symptom, insight and global illness severity ratings. Minocycline use was also associated with significant improvement in working memory and other types of executive function.
Publication
N/A
Link
N/A
PI Name
Shlomo Mendlovic
Degree
MD
Center
N/A
Institution
Shalvata Mental Health Center
Address
Alyat Hanoar St
City or Town
Hod HaSaron
State or Province
N/A
Zip or Postal Code
45100
Country
Israel
Email Address
mendlovic@clalit.org.il